Convertible note financing · Biotech

InSitu Biologics discloses $1.25m convertible note financing

The drug-delivery developer reported $1.25m sold to one investor in an offering targeting $2.5m.

InSitu Biologics disclosed $1.25 million in convertible promissory note financing in a Form D filed on August 10, 2026. The filing reports one investor and a first sale on August 4, with a total offering target of $2.5 million.

The Minnesota company develops a localized drug-delivery platform intended to release therapy near an injection site over several days. Its lead candidate, INSB200, is being developed for post-surgical pain management using a peripheral nerve-block injection.

Funding history

Convertible note financing · This round$1.3M

Sources

  1. InSitu Biologics new convertible promissory note offeringsec.gov · Aug 10, 2026
  2. insitubiologics.com
  3. insitubiologics.com